Spots Global Cancer Trial Database for localized unresectable neuroblastoma
Every month we try and update this database with for localized unresectable neuroblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma | NCT00002803 | Neuroblastoma | cyclophosphamid... doxorubicin hyd... vincristine sul... conventional su... | - 1 Year | National Cancer Institute (NCI) | |
| Biomarkers in Samples From Young Patients With Neuroblastoma | NCT01358604 | Neuroblastoma | polymerase chai... protein express... western blottin... flow cytometry immunohistochem... laboratory biom... | - 120 Years | Children's Oncology Group | |
| Combination Chemotherapy in Treating Children With Neuroblastoma | NCT00003093 | Neuroblastoma | filgrastim sargramostim carboplatin cyclophosphamid... doxorubicin hyd... etoposide conventional su... neoadjuvant the... | - 20 Years | Children's Oncology Group | |
| Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions | NCT00436696 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... | Laboratory Biom... | - | Children's Oncology Group | |
| Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma | NCT00025428 | Neuroblastoma | carboplatin cyclophosphamid... doxorubicin hyd... etoposide vincristine sul... adjuvant therap... conventional su... neoadjuvant the... | 1 Year - 18 Years | National Cancer Institute (NCI) | |
| Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | NCT00567567 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Doxorubicin Hyd... Etoposide External Beam R... Filgrastim Isotretinoin Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Thiotepa Topotecan Hydro... Vincristine Sul... | - 30 Years | Children's Oncology Group | |
| Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma. | NCT00025597 | Neuroblastoma | carboplatin cyclophosphamid... doxorubicin hyd... etoposide vincristine sul... conventional su... | - 1 Year | National Cancer Institute (NCI) | |
| Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma | NCT00033293 | Localized Resec... Localized Unres... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Clinical Observ... Cyclophosphamid... Laboratory Biom... Magnetic Resona... Prednisone Therapeutic Imm... | - 8 Years | Children's Oncology Group | |
| Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma | NCT00410631 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide phosp... ifosfamide isotretinoin melphalan topotecan hydro... vincristine sul... vindesine autologous hema... conventional su... peripheral bloo... iobenguane I 13... radiation thera... | - 21 Years | National Cancer Institute (NCI) | |
| Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors | NCT00003203 | Brain Tumors Central Nervous... Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... vincristine sul... adjuvant therap... radiation thera... | 3 Years - 21 Years | Children's Oncology Group | |
| Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | NCT00017225 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide ifosfamide melphalan tretinoin vincristine sul... vindesine autologous bone... conventional su... peripheral bloo... radiation thera... | - 20 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | NCT00004188 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... doxorubicin hyd... etoposide isotretinoin melphalan topotecan hydro... vincristine sul... autologous bone... bone marrow abl... conventional su... peripheral bloo... radiation thera... | - 30 Years | Children's Oncology Group | |
| Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma | NCT01387724 | Neuroblastoma | RNA analysis polymerase chai... protein express... proteomic profi... western blottin... enzyme-linked i... immunohistochem... laboratory biom... liquid chromato... mass spectromet... | 1 Year - 10 Years | Children's Oncology Group | |
| Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma | NCT00416676 | Neuroblastoma | carboplatin cisplatin cyclophosphamid... etoposide vincristine sul... adjuvant therap... conventional su... neoadjuvant the... radiation thera... | 1 Year - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma | NCT00030719 | Neuroblastoma | filgrastim monoclonal anti... busulfan carboplatin cyclophosphamid... etoposide isotretinoin melphalan vincristine sul... bone marrow abl... conventional su... peripheral bloo... radiation thera... | 1 Year - 20 Years | National Cancer Institute (NCI) | |
| Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma | NCT01358617 | Disseminated Ne... Localized Resec... Localized Unres... Recurrent Neuro... Stage 4S Neurob... | diagnostic labo... | - | Children's Oncology Group | |
| Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma | NCT00450307 | Neuroblastoma | monoclonal anti... sargramostim | - 21 Years | Memorial Sloan Kettering Cancer Center | |
| Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | NCT00026312 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Aldesleukin Dinutuximab Isotretinoin Laboratory Biom... Pharmacological... Quality-of-Life... Sargramostim | - 30 Years | National Cancer Institute (NCI) | |
| Observation of Young Patients With Localized Neuroblastoma Who Have Undergone Surgery Only | NCT00416559 | Long-term Effec... Neuroblastoma | clinical observ... | - 20 Years | National Cancer Institute (NCI) | |
| Studying Gene Expression in Samples From Younger Patients With Neuroblastoma | NCT01553448 | Neoplastic Synd... Neuroblastoma | gene expression... protein express... enzyme-linked i... immunohistochem... laboratory biom... medical chart r... | - 21 Years | Children's Oncology Group | |
| Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma | NCT00526318 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide phosp... ifosfamide isotretinoin melphalan topotecan hydro... vincristine sul... vindesine autologous hema... iobenguane I 13... radiation thera... | - 21 Years | National Cancer Institute (NCI) | |
| Observation of Young Patients With Localized Neuroblastoma Who Have Undergone Surgery Only | NCT00416559 | Long-term Effec... Neuroblastoma | clinical observ... | - 20 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma | NCT00025649 | Neuroblastoma | filgrastim busulfan carboplatin cyclophosphamid... doxorubicin hyd... etoposide melphalan vincristine sul... autologous bone... conventional su... peripheral bloo... | - 1 Year | National Cancer Institute (NCI) | |
| Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma | NCT00939965 | Neuroblastoma | isotretinoin DNA analysis polymerase chai... laboratory biom... pharmacological... | - 18 Years | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment | NCT00089258 | Neuroblastoma | beta-glucan monoclonal anti... sargramostim isotretinoin | - | Memorial Sloan Kettering Cancer Center | |
| R(+)XK469 in Treating Patients With Advanced Neuroblastoma | NCT00028522 | Disseminated Ne... Localized Unres... Recurrent Neuro... Regional Neurob... | R(+)XK469 | 5 Years - 20 Years | National Cancer Institute (NCI) | |
| Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma | NCT01208454 | Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Isotretinoin Laboratory Biom... Pharmacological... Vorinostat | - 30 Years | National Cancer Institute (NCI) | |
| Study of DNA in Blood Samples From Patients With Neuroblastoma | NCT00898391 | Disseminated Ne... Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4S Neurob... | laboratory biom... polymerase chai... polyacrylamide ... DNA analysis | - | Children's Oncology Group | |
| Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors | NCT00003203 | Brain Tumors Central Nervous... Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... vincristine sul... adjuvant therap... radiation thera... | 3 Years - 21 Years | Children's Oncology Group | |
| Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma | NCT00070200 | Neuroblastoma | filgrastim cisplatin cyclophosphamid... doxorubicin hyd... etoposide isotretinoin melphalan topotecan hydro... vincristine sul... conventional su... peripheral bloo... radiation thera... | - 30 Years | Children's Oncology Group | |
| Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors | NCT00281905 | Brain and Centr... Neuroblastoma | carboplatin cisplatin cyclophosphamid... methotrexate vincristine sul... radiation thera... | - 3 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma | NCT00017368 | Neuroblastoma | filgrastim sargramostim carboplatin cisplatin cyclophosphamid... doxorubicin hyd... etoposide etoposide phosp... ifosfamide isotretinoin melphalan thiotepa vincristine sul... conventional su... peripheral bloo... radiation thera... | - 30 Years | Children's Oncology Group | |
| Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma | NCT01510600 | Neuroblastoma | DNA analysis polymerase chai... laboratory biom... medical chart r... | - 30 Years | Children's Oncology Group | |
| Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma | NCT00002634 | Neuroblastoma | filgrastim monoclonal anti... cisplatin cyclophosphamid... doxorubicin hyd... etoposide mesna perfosfamide vincristine sul... autologous bone... in vitro-treate... low-LET cobalt-... low-LET photon ... radioisotope th... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Biomarkers in Young Patients With Neuroblastoma | NCT01169376 | Neuroblastoma | DNA analysis DNA methylation... RNA analysis comparative gen... mutation analys... polymorphism an... | - 30 Years | Children's Oncology Group | |
| Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma | NCT00030719 | Neuroblastoma | filgrastim monoclonal anti... busulfan carboplatin cyclophosphamid... etoposide isotretinoin melphalan vincristine sul... bone marrow abl... conventional su... peripheral bloo... radiation thera... | 1 Year - 20 Years | National Cancer Institute (NCI) | |
| Surgery in Treating Patients With Neuroblastoma | NCT00003122 | Neuroblastoma | surgical proced... | - 20 Years | National Cancer Institute (NCI) | |
| N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma | NCT01019850 | Neuroblastoma | Vorinostat 131- I Metaiodo... Peripheral Bloo... Filgrastim | 2 Years - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma | NCT00005978 | Neuroblastoma | filgrastim carboplatin etoposide melphalan autologous bone... peripheral bloo... iobenguane I 13... radiation thera... | 1 Year - 21 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma | NCT00960739 | Neuroblastoma | Topotecan hydro... Autologous hema... iobenguane I 13... total-body irra... | 1 Year - 20 Years | Centre Oscar Lambret | |
| Surgery in Treating Patients With Neuroblastoma | NCT00003122 | Neuroblastoma | surgical proced... | - 20 Years | National Cancer Institute (NCI) | |
| Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | NCT00017225 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide ifosfamide melphalan tretinoin vincristine sul... vindesine autologous bone... conventional su... peripheral bloo... radiation thera... | - 20 Years | National Cancer Institute (NCI) | |
| Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer | NCT01132547 | Cancer | cyproheptadine ... placebo | 2 Years - 21 Years | University of South Florida | |
| Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment | NCT00089258 | Neuroblastoma | beta-glucan monoclonal anti... sargramostim isotretinoin | - | Memorial Sloan Kettering Cancer Center | |
| N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma | NCT01019850 | Neuroblastoma | Vorinostat 131- I Metaiodo... Peripheral Bloo... Filgrastim | 2 Years - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma | NCT00526318 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide phosp... ifosfamide isotretinoin melphalan topotecan hydro... vincristine sul... vindesine autologous hema... iobenguane I 13... radiation thera... | - 21 Years | National Cancer Institute (NCI) | |
| N99-02: Melphalan and Buthionine Sulfoximine | NCT00005835 | Neuroblastoma | buthionine sulf... melphalan Peripheral bloo... Filgrastim | - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma | NCT00072358 | Neuroblastoma | anti-GD2 murine... anti-GD2 murine... | - | Memorial Sloan Kettering Cancer Center | |
| Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | NCT00716976 | Brain Tumor Central Nervous... Childhood Germ ... Extragonadal Ge... Liver Cancer Neuroblastoma Ototoxicity Ovarian Cancer Sarcoma | sodium thiosulf... examination | 1 Year - 18 Years | Children's Oncology Group | |
| Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma | NCT00904241 | Ganglioneurobla... Localized Resec... Localized Unres... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Cytology Specim... Laboratory Biom... | - 30 Years | Children's Oncology Group | |
| Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma | NCT00002803 | Neuroblastoma | cyclophosphamid... doxorubicin hyd... vincristine sul... conventional su... | - 1 Year | National Cancer Institute (NCI) | |
| High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma | NCT00389766 | Neuroblastoma | iodine I 131 me... topotecan hydro... chemotherapy peripheral bloo... radioisotope th... radionuclide im... radiosensitizat... total-body irra... | 1 Year - 17 Years | National Cancer Institute (NCI) | |
| Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma | NCT00471679 | Neuroblastoma | ethanol | - | Memorial Sloan Kettering Cancer Center | |
| Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma | NCT02176967 | Ganglioneurobla... Localized Resec... Localized Unres... Neuroblastoma | Biopsy Bone Marrow Asp... Bone Marrow Bio... Carboplatin Clinical Observ... Computed Tomogr... Cyclophosphamid... Doxorubicin Hyd... Etoposide Magnetic Resona... Ultrasound | - 18 Months | Children's Oncology Group | |
| Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma | NCT00276731 | Neuroblastoma | carboplatin cisplatin cyclophosphamid... etoposide vincristine sul... conventional su... neoadjuvant the... radiation thera... | 1 Year - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant | NCT00417053 | Neuroblastoma | filgrastim busulfan carboplatin cyclophosphamid... doxorubicin hyd... etoposide phosp... melphalan vincristine sul... autologous bone... bone marrow abl... conventional su... peripheral bloo... radiation thera... | - 1 Year | National Cancer Institute (NCI) | |
| Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor | NCT00003273 | Brain and Centr... Neuroblastoma Retinoblastoma Sarcoma | filgrastim carboplatin cisplatin cyclophosphamid... etoposide leucovorin calc... methotrexate temozolomide thiotepa vincristine sul... autologous bone... peripheral bloo... radiation thera... | - 10 Years | NYU Langone Health | |
| Surgery in Treating Patients With Neuroblastoma | NCT00003122 | Neuroblastoma | surgical proced... | - 20 Years | National Cancer Institute (NCI) | |
| Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | NCT01175356 | Ganglioneurobla... Localized Resec... Localized Unres... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | 3-Dimensional C... Autologous Hema... Busulfan Cisplatin Cyclophosphamid... Doxorubicin Hyd... Etoposide Phosp... External Beam R... In Vitro-Treate... Intensity-Modul... Iobenguane I-13... Isotretinoin Laboratory Biom... Melphalan Pharmacological... Questionnaire A... Therapeutic Con... Topotecan Hydro... Vincristine Sul... | 1 Year - 30 Years | Children's Oncology Group | |
| Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma | NCT00072358 | Neuroblastoma | anti-GD2 murine... anti-GD2 murine... | - | Memorial Sloan Kettering Cancer Center | |
| Biomarkers in Samples From Young Patients With Neuroblastoma | NCT01358604 | Neuroblastoma | polymerase chai... protein express... western blottin... flow cytometry immunohistochem... laboratory biom... | - 120 Years | Children's Oncology Group | |
| Study of Specimens From Young Patients With Neuroblastoma | NCT00958659 | Localized Resec... Localized Unres... Regional Neurob... Stage 4S Neurob... | laboratory biom... | - 18 Years | Children's Oncology Group | |
| R(+)XK469 in Treating Patients With Advanced Neuroblastoma | NCT00028522 | Disseminated Ne... Localized Unres... Recurrent Neuro... Regional Neurob... | R(+)XK469 | 5 Years - 20 Years | National Cancer Institute (NCI) | |
| Study of Specimens From Young Patients With Neuroblastoma | NCT00958659 | Localized Resec... Localized Unres... Regional Neurob... Stage 4S Neurob... | laboratory biom... | - 18 Years | Children's Oncology Group | |
| Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma | NCT00960739 | Neuroblastoma | Topotecan hydro... Autologous hema... iobenguane I 13... total-body irra... | 1 Year - 20 Years | Centre Oscar Lambret | |
| Protein Expression in Human Neuroblastoma Tumor Samples | NCT01407731 | Neuroblastoma | protein express... western blottin... laboratory biom... | - | Children's Oncology Group | |
| Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions | NCT00436696 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... | Laboratory Biom... | - | Children's Oncology Group | |
| Biomarkers in Samples From Young Patients With Neuroblastoma | NCT01358604 | Neuroblastoma | polymerase chai... protein express... western blottin... flow cytometry immunohistochem... laboratory biom... | - 120 Years | Children's Oncology Group | |
| Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma | NCT00276679 | Neuroblastoma | temozolomide | 1 Year - 16 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma | NCT00025649 | Neuroblastoma | filgrastim busulfan carboplatin cyclophosphamid... doxorubicin hyd... etoposide melphalan vincristine sul... autologous bone... conventional su... peripheral bloo... | - 1 Year | National Cancer Institute (NCI) | |
| N99-02: Melphalan and Buthionine Sulfoximine | NCT00005835 | Neuroblastoma | buthionine sulf... melphalan Peripheral bloo... Filgrastim | - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma | NCT02176967 | Ganglioneurobla... Localized Resec... Localized Unres... Neuroblastoma | Biopsy Bone Marrow Asp... Bone Marrow Bio... Carboplatin Clinical Observ... Computed Tomogr... Cyclophosphamid... Doxorubicin Hyd... Etoposide Magnetic Resona... Ultrasound | - 18 Months | Children's Oncology Group | |
| Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | NCT00567567 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Doxorubicin Hyd... Etoposide External Beam R... Filgrastim Isotretinoin Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Thiotepa Topotecan Hydro... Vincristine Sul... | - 30 Years | Children's Oncology Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
